摘要
目的观察晚期非小细胞肺癌(NSCLC)应用培美曲塞维持化疗的疗效以及对生存时间的影响。方法选择经一线GP(吉西他滨+顺铂)方案化疗4周期后获得疾病控制的晚期NSCIC患者36例,在完成4周期化疗后第21天开始应用培美曲塞维持化疗直至疾病进展,主要观察中位无进展生存期(MPFS)、中位生存期(MST)及不良反应情况。结果 36例晚期NSCLC患者共完成维持化疗153周期,MPFS为4.2个月,MST为9.4个月,主要不良反应为白细胞减少和疲乏,但均可忍受。结论晚期NSCLC患者化疗稳定后应用培美曲塞维持化疗是安全的,并能明显延长患者的无进展生存期,同时不良反应均可耐受。
Objective To study the clinical effect of maintenance chemotherapy by pemetrexed in advanced non-small-cell lung cancer.Methods Thirty-six patients of advanced NSCLC who received gemcitabine plus cisplatin achieving disease stabilization（CR/PR/SD） were given pemetrexed maintenance（500 mg/m2 on d1 every 21 days） until progression of disease.MPFS,MST and diverse reactions were observed.Results The cycles of maintenance chemotherapy were 153.MPFS throughout the maintenance period was 4.2 months,and MST was 9.4 months.The main side effects were leucopenia and fatigue which were tolerable.Conclusion Maintenance chemotherapy with pemetrexed following initial therapy with gemcitabine or docetaxel plus cisplatin is feasible.It can extend the PFS,and shows a favorable toxicity profile.
出处
《实用临床医药杂志》
CAS
2011年第13期48-50,共3页
Journal of Clinical Medicine in Practice
关键词
培美曲塞
维持治疗
非小细胞肺癌
non-small-cell lung cancer
maintenance chemotherapy
pemetrexed
